These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26831249)

  • 1. An Exact Procedure for the Evaluation of Reference-Scaled Average Bioequivalence.
    Tothfalusi L; Endrenyi L
    AAPS J; 2016 Mar; 18(2):476-89. PubMed ID: 26831249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Algorithms for evaluating reference scaled average bioequivalence: power, bias, and consumer risk.
    Tothfalusi L; Endrenyi L
    Stat Med; 2017 Nov; 36(27):4378-4390. PubMed ID: 28850696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration.
    Davit BM; Chen ML; Conner DP; Haidar SH; Kim S; Lee CH; Lionberger RA; Makhlouf FT; Nwakama PE; Patel DT; Schuirmann DJ; Yu LX
    AAPS J; 2012 Dec; 14(4):915-24. PubMed ID: 22972221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlling type I error in the reference-scaled bioequivalence evaluation of highly variable drugs.
    Ocaña J; Muñoz J
    Pharm Stat; 2019 Oct; 18(5):583-599. PubMed ID: 31190418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence for highly variable drugs: regulatory agreements, disagreements, and harmonization.
    Endrenyi L; Tothfalusi L
    J Pharmacokinet Pharmacodyn; 2019 Apr; 46(2):117-126. PubMed ID: 30798390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs.
    Li Z; Fang L; Jiang W; Kim MJ; Zhao L
    Curr Neurol Neurosci Rep; 2017 Sep; 17(11):82. PubMed ID: 28929357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Likelihood approach for evaluating bioequivalence of highly variable drugs.
    Du L; Choi L
    Pharm Stat; 2015; 14(2):82-94. PubMed ID: 25408492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax
    Zhang Y; Chen X; Tang Y; Lu Y; Guo L; Zhong D
    Drug Des Devel Ther; 2017; 11():2109-2119. PubMed ID: 28744102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology.
    Lechat P
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):777-787. PubMed ID: 35986193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-stage designs versus European scaled average designs in bioequivalence studies for highly variable drugs: Which to choose?
    Molins E; Cobo E; Ocaña J
    Stat Med; 2017 Dec; 36(30):4777-4788. PubMed ID: 28853164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence of Sarpogrelate in Healthy Chinese Subjects Under Fasting and Fed Conditions: A 4-Way Replicate Crossover Investigation by a Reference-Scaled Average Bioequivalence Approach.
    Ding YH; Liu B; Lou JF; Sun JX; Wu M; Zhu XX; Chen GL; Zhang H; Li XJ; Chen H; Liu CJ; Shen ZW; Li CY
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):713-720. PubMed ID: 30325583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consumer's risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs.
    Muñoz J; Alcaide D; Ocaña J
    Stat Med; 2016 May; 35(12):1933-43. PubMed ID: 26707698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approximate confidence limit for the reference scaled bioequivalence with a parallel design.
    Liao JJZ; Li Y
    J Biopharm Stat; 2020 Mar; 30(2):231-243. PubMed ID: 31455199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products of agomelatine in Chinese subjects.
    Tang F; Zhou R; Cheng Z; Yang G; Chen A; Liu Z; Tan H; Yang S; Li S; Mu L; Yu P
    Acta Pharm Sin B; 2016 Jan; 6(1):71-8. PubMed ID: 26904401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some thoughts on drug interchangeability.
    Chow SC; Song F; Chen M
    J Biopharm Stat; 2016; 26(1):178-86. PubMed ID: 26366703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence study.
    Jones B; Li B; Bagger M; Goodyear A; Ludwig I
    Pharm Stat; 2022 Nov; 21(6):1357-1365. PubMed ID: 35604539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Bioequivalence of Two Formulations of Valsartan 80 mg Capsules: A Randomized, Single Dose, 4-Period Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions.
    Wu Q; Wang X; Chen Q; Zou Y; Xu X; Li T; Yu C; Zhu F; Zhang KE; Jia J; Liu Y
    Drug Des Devel Ther; 2020; 14():4221-4230. PubMed ID: 33116410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing bioequivalence and drug interchangeability.
    Chen M; Chow SC
    J Biopharm Stat; 2017; 27(2):272-281. PubMed ID: 27936343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.